Risk stratification of patients with locally aggressive differentiated thyroid cancer: Results of the MSDS trial

NuklearMedizin

Volumn 49, Issue 3, 2010, Pages 79-84

  Riemann, Burkhard ^a   Kramer J A ^a   Schmid, K W ^b   Dralle, H ^c   Dietlein, M ^d   Schicha, H ^d   Sauerland, C ^e   Frankewitsch, T ^e   Schober, O ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b UNIVERSITY HOSPITAL ESSEN   (Germany)

^c MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^d UNIVERSITY OF COLOGNE   (Germany)

^e UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

MSDS trial; Risk stratification; Thyroid carcinomas

Indexed keywords

RADIOACTIVE IODINE;

ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EVENT FREE SURVIVAL; FEMALE; HUMAN; KAPLAN MEIER METHOD; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; RISK ASSESSMENT; THYROID CANCER; THYROIDECTOMY;

ADULT; AGED; CARCINOMA, PAPILLARY; CELL DIFFERENTIATION; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; NEOPLASM STAGING; RISK ASSESSMENT; THYROID NEOPLASMS; TIME FACTORS;

EID: 77952836050     PISSN: 00295566     EISSN: None     Source Type: Journal    
DOI: 10.3413/nukmed-0302     Document Type: Article

References (24)

1. Biermann M, Schober O. GCP-compliant management of the Multicentric Study Differentiated Thyroid Carcinoma (MSDS) with a relational database under Oracle 8i. Inform Biom Epidemiol Med Biol 2002; 33: 441-459.
2. Biermann M, Pixberg MK, Schuck A et al. Multi-center study differentiated thyroid carcinoma (MSDS). Diminished acceptance of adjuvant external beam radiotherapy. Nuklearmedizin 2003; 42: 244-250.
3. Biermann M, Pixberg M, Riemann B et al. Clinical outcomes of adjuvant external-beam radiotherapy for differentiated thyroid cancer. Nuklearmedizin 2009; 48: 89-98.
4. Byar DP, Green SB, Dor P et al. A prognostic index for thyroid carcinoma. A study of the E.O.R.T.C. Thyroid Cancer Cooperative Group. Eur J Cancer 1979; 15: 1033-1041.
5. Cooper DS, Doherty GM, Haugen BR et al. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2006; 16: 109-142.
6. Dralle H, Sekulla C, Haerting J et al. Risk factors of paralysis and functional outcome after recurrent laryngeal nerve monitoring in thyroid surgery. Surgery 2004; 136: 1310-1322.
7. Gimm O, Brauckhoff M, Thanh PN et al. An update on thyroid surgery. Eur J Nucl Med Mol Imaging 2002; 29: S447-S452.
8. Gospodarowicz MK, Miller D, Groome PA et al. The process for continuous improvement of the TNM classification. Cancer 2004; 100: 1-5. (Pubitemid 37553532)
9. Ito Y, Tomoda C, Uruno T et al. Prognostic significance of extrathyroid extension of papillary thyroid carcinoma: massive but not minimal extension affects the relapse-free survival. World J Surg 2006; 30: 780-786. (Pubitemid 43724106)
10. Ito Y, Tomoda C, Uruno T et al. Minimal extrathyroid extension does not affect the relapse-free survival of patients with papillary thyroid carcinoma measuring 4 cm or less over the age of 45 years. Surg Today 2006; 36: 12-18. (Pubitemid 43015848)
11. Ito Y, Miyauchi A, Jikuzono T et al. Risk factors contributing to a poor prognosis of papillary thyroid carcinoma: validity of UICC/AJCC TNM classification and stage grouping. World J Surg 2007; 31: 838-848.
12. Jukkola A, Bloigu R, Ebeling T et al. Prognostic factors in differentiated thyroid carcinomas and their implications for current staging classifications. Endocr Relat Cancer 2004; 11: 571-579. (Pubitemid 39331285)
13. Lerch H, Schober O, Kuwert T et al. Survival of differentiated thyroid carcinoma studied in 500 patients. J Clin Oncol 1997; 15: 2067-2075. (Pubitemid 27209538)
14. Pacini F, Schlumberger M, Dralle H et al. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol 2006; 154: 787-803.
15. Riemann B, Schober O; MSDS study group. Are "high-risk" patients with differentiated thyroid cancer "healthy patients"? Nuklearmedizin 2008; 47: 179-180.
16. Schmid KW, Wittekind C. Die missglückte Klassifikation. Pathologe 2003; 24: 338.
17. Schuck A, Biermann M, Pixberg MK et al. Acute toxicity of adjuvant radiotherapy in locally advanced differentiated thyroid carcinoma. First results of the multicenter study differentiated thyroid carcinoma (MSDS). Strahlenther Onkol 2003; 179: 832-839.
18. Sherman SI, Brierley JD, Sperling M et al. Prospective multicenter study of thyroid carcinoma treatment: initial analysis of staging and outcome. National Thyroid Cancer Treatment Cooperative Study Registry Group. Cancer 1998; 83: 1012-1021.
19. Sobin LH, Wittekind C. Thyroid gland - rules for classification. In: Sobin LH, Wittekind C (eds). UICC TNM classification of malignant tumors. New York: Wiley-Liss 1997; 47-50.
20. Sobin LH, Wittekind C. Thyroid gland - rules for classification. In: Sobin LH, Wittekind C (eds). UICC TNM classification of malignant tumors. New York: Wiley-Liss 2002; 52-56.
21. Sobin LH, Gospodarowicz MK, Wittekind C. Thyroid gland - rules for classification. In: Sobin LH, Gospodarowicz MK, Wittekind C (eds). UICC TNM classification of malignant tumors. New York: Wiley-Liss 2009; 58-62.
22. Verburg FA, Mäder U, Kruitwagen CL et al. A comparison of prognostic classification systems for differentiated thyroid carcinoma. Clin Endocrinol 2009: DOI 10.1111/j.1365-2265.2009.03734.
23. Voutilainen PE, Siironen P, Franssila KO et al. AMES, MACIS and TNM prognostic classifications in papillary thyroid carcinoma. Anticancer Res 2003; 23: 4283-4288.
24. Wittekind C, Greene FL, Henson DE et al. A commentary on uniform use. In: Wittekind C, Greene FL, Henson DE et al. (eds). TNM Supplement. New York: Wiley-Liss 2003; 138.